A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Immunomodulating Effects of Bleomycin and its Derivatives, Peplomycin and Liblomycin on Murine Antitumour Effector Cells
unpublished
INTRODUCTION Bleomycin (BLM) is an antitumour agent, which is well known for its various immunoaugmenting effects 1 such as the enhancement of interleukin-2 (IL-2) production by mitogen-stimulated spleen cells 2 , activation of macrophages 3 and the elimination of suppressor T-lymphocyte activity which might aid the host in overcoming immunosuppression 4. Its clinical use, however, is limited by toxicity to the lungs in the form of lung fibrosis 5. Peplomycin (PEP), an analogue of BLM, has a
fatcat:zmftsernqbeytk6yzfypb5mrji